AR067446A1 - Un medicamento para tratar higado graso que comprende cilostazol - Google Patents
Un medicamento para tratar higado graso que comprende cilostazolInfo
- Publication number
- AR067446A1 AR067446A1 ARP080102879A ARP080102879A AR067446A1 AR 067446 A1 AR067446 A1 AR 067446A1 AR P080102879 A ARP080102879 A AR P080102879A AR P080102879 A ARP080102879 A AR P080102879A AR 067446 A1 AR067446 A1 AR 067446A1
- Authority
- AR
- Argentina
- Prior art keywords
- medicinal product
- fat liver
- treat fat
- cilostazol
- includes cilostazol
- Prior art date
Links
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 title 1
- 229960004588 cilostazol Drugs 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007181760 | 2007-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067446A1 true AR067446A1 (es) | 2009-10-14 |
Family
ID=39689465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102879A AR067446A1 (es) | 2007-07-11 | 2008-07-03 | Un medicamento para tratar higado graso que comprende cilostazol |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8642618B2 (enExample) |
| EP (1) | EP2162134A1 (enExample) |
| JP (2) | JP5558348B2 (enExample) |
| KR (2) | KR20150038739A (enExample) |
| CN (1) | CN101778630A (enExample) |
| AR (1) | AR067446A1 (enExample) |
| CA (1) | CA2691632A1 (enExample) |
| TW (1) | TW200908973A (enExample) |
| WO (1) | WO2009008539A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101094934B1 (ko) * | 2010-10-22 | 2011-12-15 | 영남대학교 산학협력단 | 실로스타졸을 유효성분으로 함유하는 알코올성 간질환 치료 또는 예방용 약학조성물 |
| EP3263705A1 (en) * | 2016-06-28 | 2018-01-03 | DKFZ Deutsches Krebsforschungszentrum | Treatments of non-alcoholic steatohepatitis (nash) |
| CN110366425A (zh) | 2016-12-15 | 2019-10-22 | 泰伦基国际有限公司 | 一种预防动脉粥样硬化及其并发症的方法 |
| WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| EP3556385A4 (en) | 2016-12-15 | 2020-12-30 | Talengen International Limited | PROCESS FOR ALLEGING HEART DISEASE |
| WO2022240783A1 (en) * | 2021-05-11 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Methods of treating liver diseases with phosphodiesterase 3b (pde3b) inhibitors |
| AU2022339755A1 (en) * | 2021-08-31 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Treatment of liver diseases with camp responsive element binding protein 3 like 3 (creb3l3) inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3944257B2 (ja) * | 1995-12-07 | 2007-07-11 | 大塚製薬株式会社 | 肝実質細胞増殖因子産生増加剤 |
-
2008
- 2008-07-03 AR ARP080102879A patent/AR067446A1/es unknown
- 2008-07-09 JP JP2010515728A patent/JP5558348B2/ja not_active Expired - Fee Related
- 2008-07-09 CN CN200880024072A patent/CN101778630A/zh active Pending
- 2008-07-09 WO PCT/JP2008/062771 patent/WO2009008539A1/en not_active Ceased
- 2008-07-09 KR KR20157007589A patent/KR20150038739A/ko not_active Ceased
- 2008-07-09 CA CA002691632A patent/CA2691632A1/en not_active Abandoned
- 2008-07-09 KR KR1020107002982A patent/KR20100046188A/ko not_active Abandoned
- 2008-07-09 US US12/667,875 patent/US8642618B2/en not_active Expired - Fee Related
- 2008-07-09 EP EP08791177A patent/EP2162134A1/en not_active Withdrawn
- 2008-07-10 TW TW097126022A patent/TW200908973A/zh unknown
-
2013
- 2013-12-24 US US14/140,179 patent/US20140121241A1/en not_active Abandoned
-
2014
- 2014-06-04 JP JP2014115759A patent/JP2014185161A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20110039887A1 (en) | 2011-02-17 |
| US8642618B2 (en) | 2014-02-04 |
| KR20100046188A (ko) | 2010-05-06 |
| CA2691632A1 (en) | 2009-01-15 |
| WO2009008539A1 (en) | 2009-01-15 |
| CN101778630A (zh) | 2010-07-14 |
| JP5558348B2 (ja) | 2014-07-23 |
| KR20150038739A (ko) | 2015-04-08 |
| JP2014185161A (ja) | 2014-10-02 |
| US20140121241A1 (en) | 2014-05-01 |
| JP2010533166A (ja) | 2010-10-21 |
| EP2162134A1 (en) | 2010-03-17 |
| TW200908973A (en) | 2009-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6251249A2 (es) | Un medicamento que comprende un derivado un derivado de carbostirilo y donepezilo para tratar enfermedad de alzheimer | |
| DOP2009000155A (es) | Derivados de hetero-pentaciclo-fenilo fusionados, composicion farmaceutica que los comprende y usos para preparar un medicamento util para el tratamiento de una condicion mediada por p38 | |
| AR067446A1 (es) | Un medicamento para tratar higado graso que comprende cilostazol | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| AR093386A1 (es) | Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento | |
| BR112014032734A2 (pt) | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento | |
| CR20120167A (es) | Conjugados de niacina y ácidos grasos y sus usos | |
| PH12014501693A1 (en) | Antimicrobial compositions comprising dgla, 15-ohepa and/or 15-hetre and methods of use thereof | |
| CL2019002172A1 (es) | Agente terapéutico para enfermedades del hígado. | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| BR112013017953A2 (pt) | Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora | |
| UY29639A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos | |
| MX2014012742A (es) | Composicion para el tratamiento de transtornos metabólicos. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| ECSP22011746A (es) | Agentes antipalúdicos | |
| UA112418C2 (uk) | Терапевтичний болезаспокійливий засіб | |
| NI201500007A (es) | Formulación transdérmica que contiene inhibidores de cox | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| BR112022003649A2 (pt) | Inibidores conjugados de resposta ao dano no dna | |
| RU2013110517A (ru) | Средство для профилактики или лечения неалкогольного стеатогепатита | |
| CO6290762A2 (es) | Nuevos derivados quinazolin-2, 4-diona y una composicion farmaceutica para prevenir a tratar la enfermedad neurocerebral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |